Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Jan-Dec:21:15330338221097203.
doi: 10.1177/15330338221097203.

Hepatobiliary Cancers: Progress in Diagnosis, Pathogenesis, and Treatment

Kishor Pant  1 , Sergio A Gradilone  1   2
Affiliations
Editorial

Hepatobiliary Cancers: Progress in Diagnosis, Pathogenesis, and Treatment

Kishor Pant et al. Technol Cancer Res Treat. 2022 Jan-Dec.

Abstract

Hepatobiliary cancers comprise a wide range of malignancies such as hepatocellular carcinoma and cholangiocarcinoma, and they are some of the most challenging to treat human neoplasms. Due to the rarity of the illnesses, the development of treatment measures for malignancies of the gastrointestinal system is far behind. The number of patients eligible for curative treatment is limited due to cancer's aggressive nature and the difficulties of early identification. Furthermore, surgery is frequently intrusive and linked with a significant level of risk. The therapy result of hepatobiliary cancers is unsatisfactory due to these complicated variables, leaving significant space for improvement.

Keywords: cholangiocarcinoma; hepatobilarry cancer; hepatocellular carcinoma; liver cancer; signaling pathway.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting Interests: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

References

    1. Nault J-C, Villanueva A. Biomarkers for hepatobiliary cancers. Hepatology. 2021;73(Suppl 1):115-127. 10.1002/hep.31175 - DOI - PubMed
    1. Gunasekaran G, Bekki Y, Lourdusamy V, Schwartz M. Surgical treatments of hepatobiliary cancers. Hepatology. 2021;73(Suppl 1):128-136. 10.1002/hep.31325 - DOI - PubMed
    1. Benson AB, D’Angelica MI, Abbott DE, et al. Hepatobiliary cancers, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Network. 2021;19(5):541-565. 10.6004/jnccn.2021.0022 - DOI - PubMed
    1. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):6. 10.1038/s41572-020-00240-3 - DOI - PubMed
    1. Rizzo A, Brandi G. Biochemical predictors of response to immune checkpoint inhibitors in unresectable hepatocellular carcinoma. Cancer Treat Res Commun. 2021;27:100328. 10.1016/j.ctarc.2021.100328 - DOI - PubMed

Publication types

MeSH terms